Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1331254

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1331254

North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

PUBLISHED:
PAGES: 75 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market size is estimated at USD 7.15 billion in 2023, and is expected to reach USD 10.84 billion by 2028, growing at a CAGR of 8.67% during the forecast period (2023-2028).

COVID-19 significantly exacerbate Diabetes risks because the virus binds to pancreatic cells that produce insulin and could exert a toxic effect on them. In fact, they point out, studies of the earlier SARS-CoV-1 virus found that many infected patients had increased blood sugar. Drugmakers are rushing to advance potential treatments for the fast-spreading virus outbreak that has infected more people globally and so far, many were killed by the respiratory illness, according to a Reuters tally. SGLT2 inhibitors drug maker, AstraZeneca said "it is committed to finding new solutions to fight COVID-19 by investigating the application of new and existing medicines."

An FDA-approved group of prescription drugs known as SGLT2 inhibitors is used in combination with diet and exercise to decrease blood sugar levels in persons with type 2 diabetes. SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin as medications. They can be found as one-ingredient formulations or in mixtures with other diabetic medications like metformin. By encouraging the kidneys to eliminate sugar from the body through the urine, SGLT2 inhibitors reduce blood sugar levels. The FDA has not authorized SGLT2 inhibitors for use in individuals with type 1 diabetes because their safety and effectiveness in these patients have not been shown.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market Trends

Jardiance Drug Holds the Highest Share in The North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Market

An oral diabetic medication called Jardiance aids in blood sugar regulation. The way empagliflozin works is by facilitating the kidneys' removal of glucose from circulation. For individuals with type-2 diabetes mellitus, Jardiance is taken in conjunction with diet and exercise to enhance blood sugar management. In individuals with type-2 diabetes and heart disease, Jardiance is used to reduce the risk of mortality from a heart attack, stroke, or heart failure. Adults with heart failure can also take Jardiance to lower their risk of cardiovascular mortality and hospitalization for heart failure (when the heart is frail and unable to pump enough blood to the body's other organs). The FDA approved Empagliflozin/Jardiance, the third SGLT inhibitor, in August 2014. It is recommended for type-2 DM patients who are adults to improve blood glucose control in addition to diet and exercise, reduce the risk of CV adverse events in type-2 DM subjects with an underlying CV illness, and reduce the risk of CV mortality and heart failure hospitalization in adults with an underlying heart failure and decreased EF. Ertugliflozin, the most recent SGLT inhibitor to get FDA approval, is suggested for adult individuals with type-2 DM to enhance blood glucose management in addition to diet and exercise.

The Jardiance group of products, managed in partnership with Eli Lilly, saw sales increase by 25.5% in 2021. Diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and for the treatment of heart failure. Jardiance is granted the FDA Breakthrough Therapy designation and the FDA Fast Track designation. Submitted in the United States and Japan in January 2022. The FDA granted priority review for adults with heart failure independent of left ventricular ejection fraction.

Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market Region.

North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Market - IMG1

The United States is Expected to Dominate the North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT 2) Market

Due to its importance in glucose reabsorption, SGLT2 was identified as a promising pharmacological target in T2DM. While all SGLT2 inhibitors appear to be safe and effective for treating T2DM in patients, the most important difference among the individual agents is the uneven evidence base for use of these drugs as heart failure-specific therapy. The United States is considered to be a premium market space for most pharmaceutical companies, as they can price their drug at a high price than the other countries and still have high sales. The country's insurance policy, which reimburses close to 50% of the drug cost to the consumers, acts as a boon for pharmaceutical companies selling drugs. The United States is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the Country. Due to changes in lifestyle and rising obesity rates, there has been a significant rise in diabetes prevalence in the United States during the past 20 years. Diabetes is one of the chronic diseases with the fastest rate of growth in the US. Each year, 1.75 million Americans receive a diabetes diagnosis. The nation also has the highest rate of obesity, a major contributor to Type 2 diabetes. Many health issues are related to diabetes. When the population with and without diabetes is compared, those who have diabetes have a 300% higher risk of being hospitalized and, as a result, spend more money on healthcare. The likelihood of COVID-19-related significant consequences is increased in diabetics.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

North America Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Market - IMG2

North America Sodium-Dependent Glucose Co-Transporter 2 (Sglt2) Industry Overview

The market studied is consolidated with Janssen Pharmaceutical, Eli Lilly, AstraZeneca Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals holding a high market share, followed by regional manufacturers accounting for a relatively smaller share.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 63519

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Jardiance (Empagliflozin)
    • 5.1.2 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.3 Invokana (Canagliflozin)
  • 5.2 Geography
    • 5.2.1 United States
    • 5.2.2 Canada
    • 5.2.3 Rest of North America

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Janssen Pharmaceutical
    • 7.1.2 Boehringer Ingelheim Pharmaceuticals
    • 7.1.3 AstraZeneca Pharmaceuticals
    • 7.1.4 Eli Lilly
    • 7.1.5 Astellas
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 AstraZeneca Pharmaceuticals
    • 7.2.2 Eli Lilly
    • 7.2.3 Other Company Share Analyses

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!